Skip to main content

Articles Tagged With:

  • Some EOL care is not adequate

    Shortness of breath in terminally ill patients is often managed poorly, says Mark Rosenberg, DO, MBA, FACEP, chairman of emergency medicine at St. Joseph's Regional Medical Center in Paterson, NJ, and co-creator of its new Life-Sustaining Management and Alternative (LSMA) program.
  • Study shows hospice accessible

    Researchers at Mount Sinai School of Medicine have found that 98% of the U.S. population lives in communities within 60 minutes of a hospice provider, which suggests that disparities in use of hospice are not likely due to a lack of access to a hospice provider.
  • Acupuncture helps cancer treatment

    Recent studies have shown that acupuncture can help control several symptoms and side effects such as pain, fatigue, dry mouth, nausea, and vomiting associated with a variety of cancers and their treatments.
  • HIV prevention efforts mired in patient denial, physician discomfort

    New research shows that despite nearly three decades of safe sex and clean needle messages and HIV prevention work, a large proportion of people at risk for HIV infection continue to engage in high-risk behaviors.
  • Protect & Respect helps HIV+ women with condoms

    A new model HIV/AIDS prevention program uses a group skills-building and peer-group led model to build on HIV clinicians' risk reduction messages to disadvantaged women who are HIV positive.
  • Our Q&A with new AIDS United CEO

    AIDS Alert asked Mark Ishaug, president and chief executive officer of the newly-formed AIDS United of Washington, DC, to discuss why the National AIDS Fund and the national policy advocacy group AIDS Action merged and what this will mean for people living with HIV/AIDS and the clinicians providing their care. His answers are presented below in a question-and-answer (Q&A) format.
  • Anaphylaxis

    Anaphylaxis is a rapid-onset and potentially life-threatening allergic reaction.
  • FDA Notifications

    On Dec. 22, 2010, the Food and Drug Administration approved a new 200 mg etravirine (Intelence®) tablet. Etravirine was originally approved in 2008, in only a 100 mg tablet formulation. The new 200 mg dosage form can help reduce pill burden for patients taking Intelence.
  • Newspaper group vows to engage blacks in HIV fight

    The National Newspaper Publishers Association (NNPA) has joined a cooperative effort using enhanced media coverage to re-engage African Americans in the fight against HIV/AIDS.
  • AIDS Alert February 2011 Issue in PDF